Psyched Wellness Provides Comprehensive Investor Update
Psyched Wellness (CSE: PSYC) (OTCQB: PSYCF), a life sciences company focused on Amanita Muscaria mushroom products, has announced key developments in their operations. The company will conduct a Genotoxicity Study on their proprietary Amanita Muscaria Extract (AME-1), following a comprehensive review of scientific data.
The company has successfully completed a production run for AME-1 and Calm products, ensuring sufficient inventory for online and retail orders. They are actively working to secure a long-term manufacturing agreement to meet growing demand.
Additionally, their consultant Zerkalo is making progress in developing new dietary supplement products using AME-1. The company has scheduled its Annual General and Special Meeting for May 15, 2025, and is expanding their route-to-market partnerships nationwide.
Psyched Wellness (CSE: PSYC) (OTCQB: PSYCF), un'azienda nel settore delle scienze della vita focalizzata sui prodotti a base di fungo Amanita Muscaria, ha annunciato sviluppi chiave nelle proprie operazioni. L'azienda condurrà uno Studio di Genotossicità sul proprio Estratto di Amanita Muscaria (AME-1), a seguito di una revisione completa dei dati scientifici.
L'azienda ha completato con successo una produzione per AME-1 e i prodotti Calm, garantendo un'adeguata scorta per ordini online e al dettaglio. Stanno attivamente lavorando per garantire un accordo di produzione a lungo termine per soddisfare la crescente domanda.
Inoltre, il loro consulente Zerkalo sta facendo progressi nello sviluppo di nuovi prodotti di integratori alimentari utilizzando AME-1. L'azienda ha programmato la sua Assemblea Generale e Straordinaria per il 15 maggio 2025, ed è in espansione nelle partnership per il mercato a livello nazionale.
Psyched Wellness (CSE: PSYC) (OTCQB: PSYCF), una empresa de ciencias de la vida centrada en productos de hongos Amanita Muscaria, ha anunciado desarrollos clave en sus operaciones. La empresa llevará a cabo un Estudio de Genotoxicidad sobre su Extracto de Amanita Muscaria (AME-1), tras una revisión exhaustiva de los datos científicos.
La empresa ha completado con éxito una producción de AME-1 y productos Calm, asegurando suficiente inventario para pedidos en línea y al por menor. Están trabajando activamente para asegurar un acuerdo de fabricación a largo plazo para satisfacer la creciente demanda.
Además, su consultor Zerkalo está avanzando en el desarrollo de nuevos productos de suplementos dietéticos utilizando AME-1. La empresa ha programado su Junta General y Extraordinaria para el 15 de mayo de 2025, y está expandiendo sus asociaciones de ruta al mercado a nivel nacional.
사이켄드 웰니스 (CSE: PSYC) (OTCQB: PSYCF)는 아마니타 무스카리아 버섯 제품에 중점을 둔 생명 과학 회사로, 운영의 주요 발전 사항을 발표했습니다. 이 회사는 유전 독성 연구를 자사의 아마니타 무스카리아 추출물(AME-1)에 대해 실시할 예정이며, 이는 과학적 데이터에 대한 종합적인 검토를 바탕으로 합니다.
회사는 AME-1 및 Calm 제품의 생산을 성공적으로 완료하여 온라인 및 소매 주문을 위한 충분한 재고를 확보했습니다. 그들은 증가하는 수요를 충족하기 위해 장기 제조 계약을 확보하기 위해 적극적으로 노력하고 있습니다.
또한, 그들의 컨설턴트인 제르칼로는 AME-1을 사용하여 새로운 건강 보조 식품 제품을 개발하는 데 진전을 보이고 있습니다. 이 회사는 2025년 5월 15일에 연례 총회 및 특별 회의를 예정하고 있으며, 전국적으로 시장 진출 파트너십을 확장하고 있습니다.
Psyched Wellness (CSE: PSYC) (OTCQB: PSYCF), une entreprise de sciences de la vie axée sur les produits à base de champignons Amanita Muscaria, a annoncé des développements clés dans ses opérations. L'entreprise réalisera une étude de génotoxicité sur son extrait propriétaire d'Amanita Muscaria (AME-1), suite à un examen complet des données scientifiques.
L'entreprise a réussi à terminer une production pour AME-1 et les produits Calm, garantissant un inventaire suffisant pour les commandes en ligne et au détail. Ils travaillent activement à sécuriser un accord de fabrication à long terme pour répondre à la demande croissante.
De plus, leur consultant Zerkalo progresse dans le développement de nouveaux produits de suppléments alimentaires utilisant AME-1. L'entreprise a programmé son Assemblée Générale Annuelle et sa Réunion Spéciale pour le 15 mai 2025, et étend ses partenariats de mise sur le marché à l'échelle nationale.
Psyched Wellness (CSE: PSYC) (OTCQB: PSYCF), ein Unternehmen der Lebenswissenschaften, das sich auf Produkte aus dem Amanita Muscaria-Pilz konzentriert, hat wichtige Entwicklungen in seinen Betrieben angekündigt. Das Unternehmen wird eine Genotoxizitätsstudie zu seinem proprietären Amanita Muscaria-Extrakt (AME-1) durchführen, nachdem eine umfassende Überprüfung der wissenschaftlichen Daten erfolgt ist.
Das Unternehmen hat erfolgreich einen Produktionslauf für AME-1 und Calm-Produkte abgeschlossen und ausreichend Lagerbestände für Online- und Einzelhandelsbestellungen sichergestellt. Sie arbeiten aktiv daran, einen langfristigen Produktionsvertrag abzuschließen, um der wachsenden Nachfrage gerecht zu werden.
Darüber hinaus macht ihr Berater Zerkalo Fortschritte bei der Entwicklung neuer Nahrungsergänzungsmittel mit AME-1. Das Unternehmen hat seine Jahreshauptversammlung und Sonderversammlung für den 15. Mai 2025 angesetzt und erweitert seine Marktzugangs-Partnerschaften landesweit.
- Successful completion of production run for AME-1 and Calm products
- Expansion of distribution partnerships nationwide
- Development of new dietary supplements through Zerkalo partnership
- Still seeking long-term manufacturing agreement
- Additional safety studies required before market expansion
Toronto, Ontario--(Newsfile Corp. - March 14, 2025) - Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the "Company" or "Psyched"), a life sciences company focused on the production and distribution of health and wellness products derived from the Amanita Muscaria mushroom, is pleased to provide a corporate update to its shareholders.
Recent Developments
In August 2020, KGK Science ("KGK"), a licensed CRO in Canada, completed a GAP analysis and Path to Market for Psyched's flagship product as a health supplement. Throughout the fall of 2024 and into 2025, Psyched engaged various industry and regulatory experts to conduct a comprehensive review of all scientific data available in the market since the initial GAP analysis by KGK, as well as the scientific studies completed by the Company. As part of this review, Psyched Wellness is pleased to announce that it will conduct a Genotoxicity Study on its proprietary Amanita Muscaria Extract (AME-1).
"As pioneers bringing Amanita-derived products to market, Psyched Wellness is committed to ensuring that our proprietary extract, AME-1, is the safest extract available to consumers," said Jeff Stevens, CEO of Psyched. "Our team prides itself on completing the necessary scientific studies to safely bring dietary supplements to market."
The Company is also pleased to announce the successful completion of a production run for AME-1 and Calm. This production run is expected to provide Psyched with the necessary inventory to fulfill its online and retail orders for Calm and support sufficient supply of extract for the new dietary supplement being developed by Zerkalo LLC ("Zerkalo"), consultants to Psyched. Psyched continues to work towards securing a long-term manufacturing agreement to meet its growing needs and will provide further updates, as necessary, at the relevant time.
Strategic Partnerships
Zerkalo is making significant progress in developing new dietary supplement products using AME-1. The Company looks forward to sharing updates on the products and branding at the appropriate time.
Upcoming Annual General and Special Meeting (AGSM)
The Company has scheduled its next AGSM for May 15, 2025. The meeting materials including notice of meeting and record date, management information circular, form of proxy and voting instruction form (the "Materials") shall be available on the Company's profile on SEDAR+ at www.sedarplus.ca.
Psyched Wellness will be growing their route-to-market partnerships, throughout the nation. If you are interested in distributing/listing Calm, please reach out to sales@psyched-wellness.com.
For further information, please contact:
Jeffrey Stevens
Chief Executive Officer
Psyched Wellness Ltd.
Tel: 647-400-8494
Email: jstevens@psyched-wellness.com
Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.
About Psyched Wellness Ltd.:
Psyched Wellness Ltd. is a Canadian-based health supplements company dedicated to researching and producing consumer packaged goods products derived from our proprietary extract of the Amanita Muscaria mushroom, AME-1.
Cautionary Statement Regarding Forward-Looking Information
This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words "could", "intend", "expect", "believe", "will", "projected", "estimated" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company's current belief or assumptions as to the outcome and timing of such future events. The forward-looking information and forward- looking statements contained herein include, but are not limited to, statements regarding: the ability of the Company to develop Amanita Muscaria-derived products and secure long-term manufacturing contract; the sufficiency of current production run for AME-1 and Calm; the success of Zerkalo in developing new dietary supplement; the safety of Amanita Muscaria consumption and the safety and purity of any extracts thereof; and the uses and potential benefits of Amanita Muscaria.
Forward-looking information in this news release are based on certain assumptions and expected future events, namely: the Company's ability to continue as a going concern; the Company's ability to continue to develop its mushroom-derived products and associated consumer packaged goods; continued approval of the Company's activities by the relevant governmental and/or regulatory authorities; and the continued growth of the Company.
These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including but not limited to: the potential inability of the Company to continue as a going concern; risks associated with potential governmental and/or regulatory action with respect to the Company's operations; competition within the psychedelics market; risks with respect to the safety of Amanita Muscaria consumption and the safety and purity of any extracts thereof; and the risk that there is no potential benefit of Amanita Muscaria consumption.
Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.
Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect the Company's expectations as of the date hereof and are subject to change thereafter. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/244513
FAQ
What is the significance of the Genotoxicity Study for PSYCF's Amanita Muscaria Extract?
How will PSYCF's recent production run impact their supply chain?
What progress is Zerkalo making with PSYCF's AME-1 extract?
When is Psyched Wellness (PSYCF) holding their next Annual General Meeting?
